Compare ASE Technology Holding Co Ltd (ASX) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASE Technology Holding Co Ltd vs AstraZeneca plc — how do they compare? ASE Technology Holding Co Ltd trades at $39.62 (market cap $85.75B), while AstraZeneca plc trades at $158.72 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 2.9× ASE Technology Holding Co Ltd's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| ASX | AZN | |
|---|---|---|
Market Cap | $85.75B | $248.14B |
Sector | Technology | Health |
52-Week High | $45.12 | $209.48 |
52-Week Low | $9.63 | $147.06 |
Enterprise Value | $90.15B | $275.41B |
Dividend Yield | 1.08% | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASE Technology Holding (ASX) trades at $39.62, up 5.39% today, with strong technical momentum and bullish moving averages. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.29 exceeding expectations by 26%. Revenue growth accelerated to $645.39B in 2025, with net income reaching $40.02B. Recent news highlights $10.5B capital expenditure increase for AI semiconductor capacity expansion.
Outlook remains positive with 80% analyst buy ratings and projected 2026 revenue of $711.2B. Key opportunities include AI-driven demand growth and margin expansion, while risks involve high valuation multiples (P/E 47.78) and significant capital expenditure commitments. The stock shows strong institutional interest despite some position adjustments by major funds.
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
